These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 28520526)

  • 1. KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation.
    Boudreau JE; Giglio F; Gooley TA; Stevenson PA; Le Luduec JB; Shaffer BC; Rajalingam R; Hou L; Hurley CK; Noreen H; Reed EF; Yu N; Vierra-Green C; Haagenson M; Malkki M; Petersdorf EW; Spellman S; Hsu KC
    J Clin Oncol; 2017 Jul; 35(20):2268-2278. PubMed ID: 28520526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KIR and HLA genotypes predictive of low-affinity interactions are associated with lower relapse in autologous hematopoietic cell transplantation for acute myeloid leukemia.
    Marra J; Greene J; Hwang J; Du J; Damon L; Martin T; Venstrom JM
    J Immunol; 2015 May; 194(9):4222-30. PubMed ID: 25810393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.
    Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C;
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails.
    Schetelig J; Baldauf H; Heidenreich F; Massalski C; Frank S; Sauter J; Stelljes M; Ayuk FA; Bethge WA; Bug G; Klein S; Wendler S; Lange V; de Wreede LC; Fürst D; Kobbe G; Ottinger HD; Beelen DW; Mytilineos J; Fleischhauer K; Schmidt AH; Bornhäuser M
    Blood; 2020 Apr; 135(16):1386-1395. PubMed ID: 31932846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA-A alleles influencing NK cell function impact AML relapse following allogeneic hematopoietic cell transplantation.
    van der Ploeg K; Le Luduec JB; Stevenson PA; Park S; Gooley TA; Petersdorf EW; Shaffer BC; Hsu KC
    Blood Adv; 2020 Oct; 4(19):4955-4964. PubMed ID: 33049053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.
    Hsu KC; Keever-Taylor CA; Wilton A; Pinto C; Heller G; Arkun K; O'Reilly RJ; Horowitz MM; Dupont B
    Blood; 2005 Jun; 105(12):4878-84. PubMed ID: 15731175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective KIR genotype evaluation of hematopoietic cell donors is feasible with potential to benefit patients with AML.
    Shaffer BC; Le Luduec JB; Park S; Devlin S; Archer A; Davis E; Cooper C; Nhaissi M; Suri B; Wells D; Tamari R; Papadopoulos E; Jakubowski AA; Giralt S; Hsu KC
    Blood Adv; 2021 Apr; 5(7):2003-2011. PubMed ID: 33843984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia.
    Schetelig J; Baldauf H; Koster L; Kuxhausen M; Heidenreich F; de Wreede LC; Spellman S; van Gelder M; Bruno B; Onida F; Lange V; Massalski C; Potter V; Ljungman P; Schaap N; Hayden P; Lee SJ; Kröger N; Hsu K; Schmidt AH; Yakoub-Agha I; Robin M
    Front Immunol; 2020; 11():584520. PubMed ID: 33542712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.
    Venstrom JM; Pittari G; Gooley TA; Chewning JH; Spellman S; Haagenson M; Gallagher MM; Malkki M; Petersdorf E; Dupont B; Hsu KC
    N Engl J Med; 2012 Aug; 367(9):805-16. PubMed ID: 22931314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells.
    Verheyden S; Ferrone S; Mulder A; Claas FH; Schots R; De Moerloose B; Benoit Y; Demanet C
    Cancer Immunol Immunother; 2009 Jun; 58(6):855-65. PubMed ID: 18841361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.
    Cooley S; Trachtenberg E; Bergemann TL; Saeteurn K; Klein J; Le CT; Marsh SG; Guethlein LA; Parham P; Miller JS; Weisdorf DJ
    Blood; 2009 Jan; 113(3):726-32. PubMed ID: 18945962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy.
    Hsu KC; Gooley T; Malkki M; Pinto-Agnello C; Dupont B; Bignon JD; Bornhäuser M; Christiansen F; Gratwohl A; Morishima Y; Oudshoorn M; Ringden O; van Rood JJ; Petersdorf E;
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):828-36. PubMed ID: 16864053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma.
    Forlenza CJ; Boudreau JE; Zheng J; Le Luduec JB; Chamberlain E; Heller G; Cheung NK; Hsu KC
    J Clin Oncol; 2016 Jul; 34(21):2443-51. PubMed ID: 27069083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of missing KIR ligands, activating KIR genotype and haplotype on the outcome of T-cell-replete hematopoietic stem cell transplantation from HLA-identical siblings in Thai patients.
    Khanuntong S; Kuptawintu P; Upaisilpsathaporn K; Poolchareon A; Bunworasate U; Hirankarn N
    HLA; 2016 Jun; 87(6):422-31. PubMed ID: 27273744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How important is NK alloreactivity and KIR in allogeneic transplantation?
    Shaffer BC; Hsu KC
    Best Pract Res Clin Haematol; 2016 Dec; 29(4):351-358. PubMed ID: 27890259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.
    Symons HJ; Leffell MS; Rossiter ND; Zahurak M; Jones RJ; Fuchs EJ
    Biol Blood Marrow Transplant; 2010 Apr; 16(4):533-42. PubMed ID: 19961944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KIR and their HLA Class I ligands: Two more pieces towards completing the puzzle of chronic rejection and graft loss in kidney transplantation.
    Littera R; Piredda G; Argiolas D; Lai S; Congeddu E; Ragatzu P; Melis M; Carta E; Michittu MB; Valentini D; Cappai L; Porcella R; Alba F; Serra M; Loi V; Maddi R; Orrù S; La Nasa G; Caocci G; Cusano R; Arras M; Frongia M; Pani A; Carcassi C
    PLoS One; 2017; 12(7):e0180831. PubMed ID: 28686681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia.
    Cooley S; Weisdorf DJ; Guethlein LA; Klein JP; Wang T; Marsh SG; Spellman S; Haagenson MD; Saeturn K; Ladner M; Trachtenberg E; Parham P; Miller JS
    J Immunol; 2014 May; 192(10):4592-600. PubMed ID: 24748496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
    Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
    Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.